Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-A01028-31 | Other Identifier | IDRCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3.
Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions.
Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced.
This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anti-SARS-CoV2 serological status | At Day 0, a blood sample is collected by venipuncture and a questionnaire is being filled. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France. For individuals who are anti-SARS-CoV2 seronegative, the same intervention is made at Day 30 and D60. For the individuals who are anti-SARS-CoV2 seropositive, the study follow-up is stopped. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anti-SARS-CoV2 Serology | Diagnostic Test | A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France. |
| Measure | Description | Time Frame |
|---|---|---|
| Anti-SARS-Cov2 seroconversion between Day 0 and Day 60. | Change of Anti-SARS-Cov2 serological status between Day 0 and Day 60, measured in blood sample. | From Day 0 to Day 60 |
| Anti-SARS-Cov2 seroconversion between Day 0 and Day 30. | Change of Anti-SARS-Cov2 serological status between Day 0 and Day 30, measured in blood sample. | From Day 0 to Day 30 |
| Anti-SARS-Cov2 seroconversion between Day 30 and Day 60. | Change of Anti-SARS-Cov2 serological status between Day 30 and Day 60, measured in blood sample. | From Day 30 to Day 60 |
| Measure | Description | Time Frame |
|---|---|---|
| Anti-SARS-Cov2 seroprevalence at Day 0. | Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0. | Day 0 |
| Correlation between seroconversion and socio-demographic factors - sex |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The study population is composed of army training hospital staff who have not already been confirmed Covid-19 positive and who are not taking any treatment relative with Covid-19.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital d'Instuction des Armées Sainte-Anne | Toulon | 83800 | France | |||
| Hôpital d'Instruction des Armées Robert Picqué |
Not provided
| ID | Term |
|---|---|
| D011795 | Surveys and Questionnaires |
| ID | Term |
|---|---|
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Questionnaire | Other | Data concerning personal exposure factors are collected in a questionnaire:
|
|
Correlation between seroconversion (measured in blood sample) at Day 60 and sex
| Day 60 |
| Correlation between seroconversion and socio-demographic factors - age | Correlation between seroconversion (measured in blood sample) at Day 60 and age | Day 60 |
| Correlation between seroconversion and professional factors - job type | Correlation between seroconversion (measured in blood sample) at Day 60 and job type (nurse, physician, etc.) | Day 60 |
| Correlation between seroconversion and professional factors - personal protective equipment type | Correlation between seroconversion (measured in blood sample) at Day 60 and personal protective equipment type | Day 60 |
| Correlation between seroconversion and non-professional factors - contact with infected individuals | Correlation between seroconversion (measured in blood sample) at Day 60 and contact with infected individuals | Day 60 |
| Correlation between seroconversion and non-professional factors - wearing of professional equipment | Correlation between seroconversion (measured in blood sample) at Day 60 and wearing of professional equipment | Day 60 |
| Correlation between seroconversion and non-professional factors - respect of barrier gestures | Correlation between seroconversion (measured in blood sample) at Day 60 and respect of barrier gestures | Day 60 |
| Villenave-d'Ornon |
| 33882 |
| France |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |